Form 8-K - Current report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2023

BIMI International Medical Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-34890		02-0563302
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

725 5th Avenue, 15th Floor, 15-01

New York NY

10022

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: 212 542 0028

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value		BIMI		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On October 30, 2023, BIMI International Medical Inc. (the “Company” or the “Registrant”) issued two press releases. The first press release announced the appointment by its subsidiary, Phenix Bio Inc. (“Phenix”), of Hao Mu Pte. Ltd. (“Hao Mu”), a Singapore company, as its non-exclusive distributor for its 17 herbal supplements in Mainland China. A copy of this press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

The second press release announced Phenix’s appointment of Hao Mu as its exclusive distributor for its herbal supplements in Hong Kong, Taiwan, and Macau. A copy of this press release is filed herewith as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01. Financial Statement and Exhibits.

Exhibit No		Document
99.1		Press Release dated October 30, 2023
99.2		Press Release dated October 30, 2023

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 30, 2023	BIMI International Medical Inc.

	By:	/s/ Tiewei Song
	Name:	Tiewei Song
	Title:	Chief Executive Officer

Exhibit 99.1

BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc’s Appointment of Mainland China Non-Exclusive Distributor

NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company (“Hao Mu”), as a distributor responsible for the distribution of Phenix’s 17 herbal supplements in Mainland China.

Pursuant to the terms of a sales agreement entered into on October 29, 2023, Hao Mu must make annual purchases of at least $5 million in order to maintain its distributor status for this territory.

Under the terms of this agreement, Phenix’s comprehensive portfolio of high-quality herbal supplements will be made available to consumers in Mainland China through Hao Mu’s well-established distribution channels and network.

“Expanding our partnership with Hao Mu to Mainland China shows our faith in Hao Mu and its ability to make our products available to wider markets” stated Tiewei Song, CEO of BIMI.

This extension of its partnership with Hao Mu evidences BIMI’s commitment to deliver world-class healthcare solutions and services to a broader global audience. Representatives from BIMI, Phenix, and Hao Mu, including BIMI’s Chief of Staff, Mr. Symington Smith, and Hao Mu’s Chief Executive Officer, Mr. Liu Yubao, attended a signing ceremony held at BIMI’s headquarters in New York City.

About BIMI International Medical Inc.

BIMI International Medical Inc. is a healthcare products and services provider, offering a broad range of healthcare products and related services in the U.S. and Asia. For more information, please visit www.usbimi.com.

About Hao Mu Pte. Ltd

Hao Mu Pte Ltd is a service and distribution company in Singapore with a strong market presence within the ASEAN region. It is dedicated to offering top-quality products and services.

Safe Harbor Statement

Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to, the Company’s ability to achieve profitable operations, its ability to continue to operate as a going concern, its ability to continue to meet NASDAQ continued listing requirements, the effects of the spread of COVID-19, the demand for the Company’s products and services, general economic conditions and other risk factors detailed in the Company’s annual report and other filings with the United States Securities and Exchange Commission.

Investor Relations Contact

Investor Relations Department of BIMI International Medical Inc.

Email: vinson@usbimi.com
Tel: +1 949 981 6274

Exhibit 99.2

BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc’s Appointment of Hong Kong, Taiwan, and Macau Exclusive Distributor

NEW YORK, NY, Oct. 30, 2023 — BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company (“Hao Mu”), as its exclusive distributor responsible for the distribution of Phenix’s 17 herbal supplements in Hong Kong, Taiwan and Macau.

Pursuant to the terms of a sales agreement entered into on October 29, 2023, Hao Mu must make annual purchases of at least $5 million in order to maintain its exclusive distributor status for this territory.

Under the terms of this agreement, Phenix’s comprehensive portfolio of high-quality herbal supplements will be made available to consumers in Hong Kong, Taiwan and Macau through Hao Mu’s well-established distribution channels and network.

“We are excited to extend our agreement with Hao Mu,” stated Tiewei Song, CEO of BIMI. “Expanding our cooperation with Hao Mu will allow us to materialize our vision of making top-tier herbal supplements accessible to individuals throughout Hong Kong, Taiwan and Macau.”

Hao Mu was previously appointed as Phenix’s exclusive distributor for the ten-member ASEAN countries. If Hao Mu is successful in meeting its minimum annual purchase of $5 million for each of its three territories, the ten-member ASEAN countries, Mainland China, and Hong Kong, Taiwan and Macao, it will result in minimum annual sales of $15 million or minimum aggregate sales of $75 million for the next five years of Phenix’s herbal supplements. No assurance can be given that Hao Mu will be successful in reaching these annual minimums.